Evidence map›Paper›PMID 40070069›Full record

ReviewCurrent drug targets2025

The Role of Glycolipids and their Toxicity in the Context of Nanomaterials and Nanoparticles: A Review of the Literature.

Moyu Li, Wenjin Peng, Siwei Zhu, Xianyu Chen, Li Li, Xiaolan Li, Chengfu Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Moyu LiHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Wenjin PengHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Siwei ZhuHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Xianyu ChenHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Li LiHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Xiaolan LiThe Second People's Hospital of China Three Gorges University, Yichang, 443002, China.
Chengfu YuanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.

Funding

innovational group project of Hubei Province Natural Science Foundation in China 2021CFA015National Natural Science Foundation of China 82174035, 82374107, 81974528, 81773959Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China 2023KZL01
6 · The paper itself

Abstract

introductionDiseases triggered by glucose and lipid metabolic disorders, such as hyperglycemia and hyperlipidemia, have become a global health threat. According to statistics, diabetic patients have exceeded 463 million worldwide, and the prevalence of hyperlipidemia is also continuously rising. These glycolipid metabolic diseases not only significantly increase the risk of complications such as cardiovascular disease, stroke, and kidney disease but also impose a huge economic burden on the global healthcare system. Despite the continuous emergence of treatment methods for glucose and lipid metabolic diseases with the advancement of research technology, existing therapies still face many challenges. In recent years, the rapid development of nanotechnology has injected new vitality into the medical field. As an emerging research field, nanomedicine has attracted much attention for its application prospects in the treatment of glycolipid metabolic diseases. Nanotechnology is expected to provide more precise and efficient solutions for the treatment of these diseases, thereby reducing global health and economic pressures.

objectiveThe objective of this article is to comprehensively review the relationship between nanotechnology and glucose and lipid metabolism.

methodsWe have carried out a series of literature searches, focusing on glycolipid effects and toxicity of nano-materials.

resultsNanoparticles as drug carriers or nanoparticles enhance bioavailability and activity. Nano-material-based optical reporters aid in detecting lysosome lipid content, facilitating treatment and drug development for glucose and lipid metabolism disorders. Additionally, nanomaterials find applications in glucose biofuel cells and microalgal lipid metabolism regulation. However, nanomaterials, such as polystyrene nanoplastics, may have toxic effects, inducing macrophage transformation and lipid accumulation in the liver.

conclusionThe development of nanotechnology is still in its infancy, and many disease-based studies are still in the stage of animal experiments and have not yet been applied in clinical practice. However, the universality and multilateralism of the use of nanotechnology give it excellent development prospects and also provide a research direction for medical research.

Indexed as

GlycolipidsNanoparticlesNanostructuresAnimalsDrug CarriersHumansLipid MetabolismNanomedicineDrug CarriersGlycolipidsglucose metabolismGlycolipidhyperglycemia.lipid metabolismnanomaterialtoxicity

Identifiers

PMID40070069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.